SMO CLINPLUS CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.5 CNY | -0.98% |
|
-1.83% | -29.92% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 912M 126M 172M | Sales 2025 * | 1.06B 147M 200M | Capitalization | 2.72B 376M 513M |
|---|---|---|---|---|---|
| Net income 2024 * | 162M 22.38M 30.53M | Net income 2025 * | 193M 26.66M 36.37M | EV / Sales 2024 * | 2.98 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.56 x |
| P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
14.1
x | Employees | 4,061 |
| Yield 2024 * |
0.29% | Yield 2025 * |
0.36% | Free-Float | 45.95% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.98% | ||
| 1 week | -1.83% | ||
| Current month | -1.35% | ||
| 1 month | +0.77% | ||
| 3 months | -3.93% | ||
| 6 months | -39.04% | ||
| Current year | -29.92% |
1 week
44.04
45.66
1 month
41.6248.77
Current year
33.6064.75
1 year
33.6075.20
3 years
33.6085.61
5 years
33.6085.61
10 years
33.6085.61
| Managers | Title | Age | Since |
|---|---|---|---|
Hong Wei Yang
FOU | Founder | 47 | 08-12-31 |
Wei Hong Song
DFI | Director of Finance/CFO | 53 | 15-11-30 |
Xiao Long Lai
BRD | Director/Board Member | 52 | 16-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hua Sheng Huang
BRD | Director/Board Member | 55 | 20-03-16 |
Xue Liu
BRD | Director/Board Member | 62 | 20-03-16 |
De Yong Tan
BRD | Director/Board Member | 48 | 18-08-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 44.5 | -0.98% | 642,700 |
| 24-05-20 | 44.94 | +0.83% | 673,100 |
| 24-05-17 | 44.57 | -0.04% | 618,763 |
| 24-05-16 | 44.59 | +1.02% | 1,108,374 |
| 24-05-15 | 44.14 | -2.63% | 1,209,750 |
End-of-day quote Shenzhen S.E., May 20, 2024
More quotes
SMO Clinplus Co Ltd is a China-based company principally engaged in the provision of Site Management Organization (SMO) services. The Company mainly provides SMO services for domestic and foreign pharmaceutical companies, medical device companies and clinical research and development of some health-related products. The Company provides customers with services including pre-preparation planning, start-up of test sites, on-site execution and full-process management of projects. The Company operates its businesses both in the domestic market and overseas markets.
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
44.5
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.92% | 380M | |
| -22.91% | 8.54B | |
| +67.47% | 4.32B | |
| -0.25% | 2.53B | |
| -39.22% | 2.48B | |
| -8.65% | 1.9B | |
| -17.46% | 1.59B | |
| -40.70% | 1.23B | |
| +13.38% | 1.13B | |
| +16.80% | 994M |
- Stock Market
- Equities
- 301257 Stock
